Pharminent

GSK looks to exit rare diseases

The British drugmaker is putting its rare disease business up for sale amid a company-wide refocusing. http://www.biopharmadive.com/news/glaxosmithkline-gsk-rare-disease-sell-divest-strimvelis/448087/

Filed under: Company